Research programme: photodynamic therapy - Photopharmica

Drug Profile

Research programme: photodynamic therapy - Photopharmica

Alternative Names: PPA 605; PPA 898; PPA XXX; PPA YYY; PPA ZZZ

Latest Information Update: 20 Mar 2007

Price : $50

At a glance

  • Originator Photopharmica
  • Class Phthalocyanines
  • Mechanism of Action Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Preclinical Bacterial infections; Cancer

Most Recent Events

  • 20 Mar 2007 Preclinical development is ongoing
  • 21 Aug 2003 Preclinical trials in Cancer in United Kingdom (unspecified route)
  • 21 Aug 2003 Preclinical trials in Bacterial infections in United Kingdom (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top